ACADIA Pharmaceuticals Inc. EBITDA

EBITDA of ACAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBITDA growth rates and interactive chart. Earnings before interest, tax, depreciation and amortization (EBITDA) is a measure of a company's operating performance. Essentially, it's a way to evaluate a company's performance without having to factor in depreciation, interest expenses (debt), writedowns or other accounting measures and taxes. EBITDA, however, can be misleading because it strips out the cost of capital investments like property, plant, and equipment. To calculate EBITDA, take operating profit (also called EBIT) and add back depreciation and amortization.


Highlights and Quick Summary

  • EBITDA for the quarter ending December 30, 2020 was $-13.5 Million (a -58.21% decrease compared to previous quarter)
  • Year-over-year quarterly EBITDA decreased by -84.78%
  • Annual EBITDA for 2020 was $-231 Million (a -5.3% decrease from previous year)
  • Annual EBITDA for 2019 was $-244 Million (a -0.27% decrease from previous year)
  • Annual EBITDA for 2018 was $-244 Million (a -15.62% decrease from previous year)
  • Twelve month EBITDA ending December 30, 2020 was $-178 Million (a -19.18% decrease compared to previous quarter)
  • Twelve month trailing EBITDA decreased by -28.17% year-over-year
Trailing EBITDA for the last four month:
30 Dec '20 29 Sep '20 29 Jun '20 30 Mar '20
$-178 Million $-220 Million $-234 Million $-248 Million
Visit stockrow.com/ACAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBITDA of ACADIA Pharmaceuticals Inc.

Most recent EBITDAof ACAD including historical data for past 10 years.

Interactive Chart of EBITDA of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. EBITDA for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-13.52 $-32.36 $-43.29 $-88.85 $-230.85
2019 $-55.76 $-45.83 $-57.39 $-87.86 $-243.78
2018 $-66.66 $-60.69 $-63.43 $-54.23 $-244.44
2017 $-69.46 $-64.79 $-67.54 $-88.2 $-289.7
2016 $-77.66 $-71.42 $-71.46 $-50.36 $-270.99
2015 $-45.6 $-39.67 $-40.04 $-40.72 $-166.03
2014 $-28.36 $-24.58 $-22.0 $-17.6 $-92.54
2013 $-11.54 $-10.33 $-8.82 $-6.01 $-36.69
2012 $-6.77 $-2.32 $-5.51 $-6.31 $-20.91
2011 $-5.42 $-5.04 $-6.48 $-5.52 $-22.46
2010 $29.21 $-4.14 $-4.16 $15.58

Business Profile of ACADIA Pharmaceuticals Inc.

Sector: Healthcare
Industry: Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.